Investor Webinar Presentation
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
5 September 2024
Investor Webinar
Melbourne, Australia; 5 September 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the
“Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds
shareholders that CEO and Managing Director, Dr Kilian Kelly, will host an investor webinar today,
Thursday 5 September at 9:30am AEST.
Attendees are required to register in advance for the webinar – using the following link:
https://us02web.zoom.us/webinar/register/WN_6EonNDzjQKG8-TXKkBc0Dg
Upon registration, attendees will receive a link to access the webinar.
A copy of the presentation to be delivered during the webinar is attached to this announcement.
-ENDSAuthorised for release by Dr Kilian Kelly, CEO & Managing Director
CONTACTS:
Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@littlebigdeal.au
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the
development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges
of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to
achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation
of multiple donors.
Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of
steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well
as trials of Cymerus products in osteoarthritis (Phase 3 – patient enrolment completed) and diabetic foot ulcers (DFU – patient enrolment
completed) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also
demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic
pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service
provider, Automic Group.
Cynata Therapeutics Limited
ABN – 98 104 037 372
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia
T: +613 7067 6940
E: info@cynata.com
www.cynata.com
A Clinical Stage Next
Generation Stem Cell
Therapeutics Company
Investor Webinar
5 September 2024
Important information
Summary information
This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries
(CYP, or Cynata) which is current as at 5 September 2024. This Presentation should be read in
conjunction with CYP’s other periodic and continuous disclosure information lodged with the Australian
Securities Exchange (ASX), which are available at www.asx.com.au.
Not an offer
This Presentation is not a prospectus, product disclosure statement or other offering document under
Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for
information purposes only and is not an invitation or offer of securities for subscription, purchase or sale
in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic
copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you
should observe such restrictions. Any non-compliance with these restrictions may contravene applicable
securities laws.
Not investment advice
Forward-looking statements
This Presentation contains certain ‘forward looking statements’, which can generally be identified by the
use of forward looking words such as ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’,
‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’
and other similar expressions. The forward looking statements contained in this Presentation are not
guarantees or predictions of future performance and involve known and unknown risks and uncertainties
and other factors, many of which are beyond the control of CYP, its directors and management, and
may involve significant elements of subjective judgment and assumptions as to future events which may
or may not be correct. There can be no assurance that actual outcomes will not differ materially from
these forward looking statements. A number of important factors could cause actual results or
performance to differ materially from the forward looking statements. No representation or warranty,
express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.
The forward looking statements are based on information available to CYP as at the date of this
Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its
directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide
any additional or updated information whether as a result of new information, future events or results or
otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements.
This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal
advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has
been prepared without taking account of any person’s individual investment objectives, financial
situation or particular needs. Before making an investment decision, prospective investors should
consider the appropriateness of the information having regard to their own investment objectives, Industry and Market data
financial situation and needs and seek legal, accounting and taxation advice appropriate to their
Certain market and industry data used in connection with this Presentation may have been obtained
jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.
from research, surveys or studies conducted by third parties, including industry or general publications.
Neither CYP nor its representatives have independently verified any such market or industry data
Investment risk and past performance
An investment in CYP securities is subject to known and unknown risks, some of which are beyond the provided by third parties or industry or general publications.
control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of Disclaimer
CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future
To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate,
CYP performance including future share price performance.
directors, officers, partners, employees and agents (Related Persons) exclude and disclaim all liability,
including without limitation for negligence, for any expenses, losses, damages or costs arising from this
Financial data
All financial information in this Presentation is in Australian currency (A$) unless otherwise stated. This Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted
Presentation contains historical financial information based on financial information that has been by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the
disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures currency, accuracy, reliability or completeness of information in this Presentation and disclaim any
obligation or undertaking to release any update or revision to the information in this Presentation to
in this Presentation are due to rounding.
reflect any change in expectations or assumptions. Statements made in this Presentation are made only
as at the date of this Presentation. The information in this Presentation remains subject to change
without notice.
2
Company highlights
Revolutionary Cymerus
manufacturing platform
• Mesenchymal stem cells (MSCs)1 have shown potential to treat a wide range of illnesses2
• However, standard manufacture requires ongoing supply of donors → challenges with consistency, potency and scale
• The induced pluripotent stem cell (iPSC)-based Cymerus platform overcomes this major obstacle by enabling
production of an effectively limitless number of consistent MSC doses from a single blood donation
Cynata is the leader of the burgeoning iPSC field
•
First completed iPSC clinical trial worldwide
•
US FDA Orphan Drug Designation3 and cleared IND4
•
Compelling clinical data generated in acute graft versus host disease (aGvHD)5 and diabetic foot ulcer (DFU)6
•
Four active clinical programs (including ongoing Phase 2 & Phase 3 trials)
•
Three randomised controlled clinical trial readouts upcoming between late 2024 and early 2026
1.
2.
3.
Also known as mesenchymal stromal cells
Zhou J, Shi Y. Cell Mol Immunol 20, 555–557 (2023)
CYP-001 granted Orphan Drug Designation for treatment of aGvHD – qualifies Cynata
for incentives including extended marketing exclusivity, tax credits and fee waivers
4.
5.
6.
IND = Investigational New Drug application – the clearance required from FDA to conduct clinical trials
Completed Phase 1 clinical trial in steroid-resistant aGvHD;
Initial data in first 16 patients (n=8 per group) after 10 weeks; final results in all 30 patients expected in
Q4 2024/Q1 2025
3
FY 2024 – a year of progress
Multiple clinical trials advanced
• Phase 3 osteoarthritis trial – patient enrolment completed in November 2023
• Global Phase 2 aGvHD trial – first patient enrolled in March 2024
• Phase 1 DFU trial – patient enrolment completed in April 2024
• New kidney transplant trial approved and ready to commence
Further encouraging clinical efficacy data
• Promising initial data from ongoing DFU trial released in February 2024
• Additional data from Phase 1 GvHD trial published in Nature Medicine in May 2024
Senior management team strengthened
• Dr Mathias Kroll commenced in new position of Chief Business Officer in April 2024: position created to
drive next stage of commercial growth
1. Initial data in first 16 patients (n=8 per group) after 10 weeks; final results in all 30 patients expected in late 2024/early 2025
4
Advanced and diverse clinical pipeline
Partnered
Cynata Sponsored
Indication
Acute Graft vs Host Disease (aGvHD)
CYP-001
FDA Orphan Designation
Diabetic Foot Ulcers (DFU)
CYP-006TK
Osteoarthritis (OA)
CYP-004
(managed by USYD, funded by NHMRC)
Kidney Transplantation
CYP-001
(managed and funded by LUMC)
Trial phase
Upcoming catalysts*
Phase 2
ongoing
Enrolment completion – Q4 2024
Phase 1
ongoing
Results – 2H 2025
Market opportunity
US$600m1
Results – Q4 2024/Q1 2025
US$9.6bn2
Results – 1H 2026
US$11.6bn3
(enrolment complete)
Phase 3
ongoing
(enrolment complete)
Phase 1/2
approved
Enrolment start – Q3 2024
Cohort 1 results – Q1 2025
US$5.9bn4
1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026); 2. Zion Market Research, 2019 (represents global treatment market in 2025); 3. Persistence Market
Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant
Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019
USYD = University of Sydney; NHMRC = National Health and Medical Research Council; LUMC = Leiden University Medical Center
* Timing of events is approximate, based on the Company’s information as at the date of this presentation, and subject to change
5
Revolutionary iPSC-based
Cymerus Manufacturing
Platform
Therapeutic potential of MSCs
Mesenchymal stem cells1 (MSCs):
• Promote an immunomodulatory
environment2
• The “sensor and switcher of the
immune system”3
• Promote tissue repair and
regeneration
• Can be used without matching
donors to recipients
• Can be engineered to express other
functional/therapeutic molecules
• However, with conventional
manufacturing methods, there are
consistency, potency and scalability
challenges
1.
2.
3.
Also known as mesenchymal stromal cells
Kelly and Rasko, Front. Immunol. 12:761616 (2021)
Sarsenova et al, Front. Immunol.13:1010399 (2022)
7
Advantages of iPSC-based platform
Induced pluripotent stem cells (iPSCs):
• Mature adult cells reprogrammed to become
pluripotent, which means:
• Effectively limitless proliferation capacity
• Potential to differentiate into any adult cell
type (including MSCs)
• Similar properties to embryonic stem cells …
but iPSCs are derived from adult donors, so
they avoid ethical controversy associated with
embryonic stem cells
→ iPSCs are ideal starting material for
commercial production of cellular products
8
Conventional MSC process
Ongoing need
for new donors
MSC isolation
Small number of MSCs
per donation
Substantial interdonor variability
Cymerus
One donor,
one time
Avoids inter-donor
variability
Culture expansion
Extensive MSC culture
expansion required
iPSC-based process
Reprogramming &
iPSC expansion
Effectively limitless
expansion potential
Robust patent protection
Differentiation into MSCs
& culture expansion
Minimal MSC
culture expansion
Major challenges:
•
MSCs undergo functional changes
and loss of potency during
extensive culture expansion
•
Continuously finding and testing new
donors is logistically challenging
•
Inter-donor variability –
inconsistent activity in MSCs from
different donors
Advantages of Cymerus
platform:
•
Effectively limitless iPSC
expansion potential
•
Avoids need for new donors
•
Avoids inter-donor variability
•
Avoids extensive MSC culture
expansion
•
High level of potency, consistency
and scalability
9
Partnering Strategy
Commercial partnering
Commercial partnering potential
underpinned by: (i) compelling clinical
data; and (ii) scalable, commercial
grade manufacturing platform
Several distinct products in
development → potential for multiple
partnerships
Platform also available to partners
pursuing other indications and/or
engineered MSC applications
11
Industry connections
• We are enhancing our individual outreach to selected organisations, which will be accelerated
by upcoming catalysts
• We attend leading conferences in our sector, to tell our story and open new discussions
• Following on from multiple events earlier this year (including Advanced Therapies, ISCT, BIO
and bone marrow transplantation conferences), our six-month event outlook includes:
Alliance for Regenerative Medicine
Company presentation and
partnering meetings
AusBiotech National Conference
Chairing panel discussion on
iPSC opportunities
Phoenix, October 2024
Melbourne, October/November 2024
JP Morgan BioWeek/Biotech Showcase Company presentation and
San Francisco, January 2025
partnering meetings
Advanced Therapies Congress
London, March 2025
Company presentation and
partnering meetings
12
Compelling Clinical Data:
CYP-001 for aGvHD
CYP-001: Two Nature Medicine publications
• CYP-001 has been granted Orphan Drug Designation
by the US FDA for the treatment of GvHD
• Phase 1 trial of CYP-001 was the first completed
clinical trial worldwide with any iPSC-derived product
14
1. CYP-001 is Cynata’s Cymerus iPSC-derived MSC product candidate for intravenous infusion
CYP-001 vs other treatments in SR-aGvHD
Overall Response
at Day 28
Overall Response
at Day 56-601
Overall Survival
at 18 months
CYP = CYP-001 in Phase 1 trial (NCT02923375)
Rux = ruxolitinib in Phase 3 trial (NCT02913261)
(ruxolitinib is now approved for SR-aGvHD)
BAT = “best available therapy” control arm in ruxolitinib
Phase 3 trial (NCT02913261)
BAT
Rux
CYP
BAT
Rux
CYP
BAT
Rux
CYP
•
Overall response rate for CYP-001
increased between D28 and D60
•
Overall response rates for BAT and
Rux declined between D28 and D56
•
Overall survival rate for CYP-001
was 60% at both 18 and 24 months
•
Overall survival rates for BAT and
Rux were 36% and 38% at 18
months, and not evaluable at 24
months
•
No serious adverse events/safety
concerns related to CYP-001
identified, but potentially serious
adverse reactions to ruxolitinib
are common
Note: comparisons are for illustrative purposes only; data taken from different clinical trials with different sample sizes (BAT: n=155; Rux: n=154; CYP-001: n=15).
D28/D56 time points used for response rate comparison as D28/D56 were the only response rate time points reported in the BAT/Rux clinical trial (NCT02913261)
1. Overall Response at Day 56-60 refers to Day 56 response for BAT & Rux, and Day 60 response for CYP-001.
15
CYP-006TK for DFU
CYP-006TK – a novel topical MSC product
• CYP-006TK utilises a
proprietary surface-coating,
optimised for the delivery
of MSCs directly to the
wound bed
iPSC-derived MSCs
• Technology exclusively
licenced to Cynata by
Tekcyte Limited
(agreement for Cynata to
acquire this IP outright
announced 1 July 2024)
17
DFU | Phase 1 clinical trial – initial data
Product: CYP-006TK (topical Cymerus
MSC wound dressing)
•
Ongoing trial in non-healing diabetic foot ulcer (DFU)
•
Patients randomised to receive standard of care (SoC) or CYP-006TK for 4 weeks, followed by SoC
•
In the first 16 patients enrolled in the trial (8 per group), after 10 weeks’ follow-up, the median reduction
in wound surface area was:
•
87.6% in the active CYP-006TK group
•
compared to 51.1% in SoC group
Example of ulcer healing in patient treated with CYP-006TK:
Day 0
Day 28
For further information: https://clinicaltrials.gov/study/NCT05165628
18
Outlook
Upcoming catalysts*
Results of three randomised controlled clinical trials expected between late 2024 and early 2026
Phase 1/2
kidney
transplant
First
patient
enrolled
Phase 2
aGvHD
Enrolment
complete
Results
Completion
Results of enrolment
Phase 1
DFU
Phase 3
osteoarthritis
Results
(Cohort 1)
Results
Results
Results
Start of
enrolment
Q3
2024
Q4
2024
Q1
2025
Q2
2025
Q3
2025
Q4
2025
* Timing of events is approximate, based on the Company’s information as at the date of this presentation, and subject to change
Q1
2026
Q2
2026
20
Summary
Next generation stem • Leading platform technology in burgeoning stem cell sector
cell company
• Diverse and highly credentialed leadership team with proven experience
Scalable
manufacturing
Compelling
clinical data
Rich clinical
pipeline
Significant growth
potential
•
Cymerus
manufacturing technology protected by robust patent portfolio
•
Enables scalable production of consistent MSCs from a single donation from a
single donor, overcoming major challenges with conventional approaches
•
Very encouraging safety and efficacy results from aGvHD clinical trial (CYP-001)
•
Promising initial data from ongoing DFU clinical trial (CYP-006TK)
•
Broad pipeline with four active clinical programs
•
FDA cleared IND for Phase 2 aGvHD clinical trial; study underway
•
Patient enrolment complete in DFU & OA clinical trials
•
Commencement of kidney transplantation clinical trial imminent
•
Global estimated market opportunity across targeted indications of ~US$28bn1
•
Focus on indications with significant unmet need
•
Proactive B-2-B outreach to drive partnering strategy
1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026); 2. Zion Market Research, 2019 (represents global treatment market in 2025); 3. Persistence Market
Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant
Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019
21
Contact Us
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street
Cremorne
Victoria 3121
Australia
cynatatherapeutics
info@cynata.com
@cynatastemcells
www.cynata.com
cynata-therapeutics
Share your feedback
Discover